Current therapies for pulmonary arterial hypertension

Seminars in Cardiothoracic and Vascular Anesthesia

Volumn 11, Issue 2, 2007, Pages 137-148

  Takaoka, Shanon ^a   Faul, John L ^a   Doyle, Ramona ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Interventions; Medical treatments; Pulmonary arterial hypertension

Indexed keywords

ADENOSINE; AMBRISENTAN; AMLODIPINE; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DILTIAZEM; DIURETIC AGENT; DOBUTAMINE; ENDOTHELIN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; HYDRALAZINE; ILOPROST; INOTROPIC AGENT; MILRINONE; NIFEDIPINE; NITRATE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; PROSTANOID; SILDENAFIL; SITAXSENTAN; TADALAFIL; UNINDEXED DRUG; UNIPROST; VERAPAMIL; WARFARIN;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ANEMIA; CHEMICAL TERATOGENESIS; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE CLASSIFICATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; ENDARTERECTOMY; EPISTAXIS; FLUSHING; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HEART AFTERLOAD; HEART CATHETERIZATION; HEART DISEASE; HEART FAILURE; HEART LUNG TRANSPLANTATION; HEART PRELOAD; HEART RIGHT VENTRICLE FAILURE; HEART SURGERY; HEART TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; INDUCED HYPOTENSION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INOTROPISM; JAW DISEASE; LIVER TOXICITY; LUNG TRANSPLANTATION; PAIN; PATHOPHYSIOLOGY; PULMONARY HYPERTENSION; RECOMMENDED DRUG DOSE; REVIEW; SCLERODERMA; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOSIS; UNSPECIFIED SIDE EFFECT;

ANTIHYPERTENSIVE AGENTS; HEART FAILURE, CONGESTIVE; HEART TRANSPLANTATION; HUMANS; HYPERTENSION, PULMONARY; LUNG TRANSPLANTATION; PHOSPHODIESTERASE INHIBITORS; PROSTAGLANDINS; RECEPTORS, ENDOTHELIN;

EID: 34249801782     PISSN: 10892532     EISSN: None     Source Type: Journal    
DOI: 10.1177/1089253207301356     Document Type: Review

References (87)

1. Burrows F., Klinck J., Rabinovitch M., Bohn D. Pulmonary hypertension in children: perioperative management. Can Anaesth Soc J. 1986 ; 33: 606-628.
2. Rodriguez R., Pearl R. Pulmonary hypertension and major surgery. Anesth Analg. 1998 ; 87: 812-815.
3. Ramakrishna G., Sprung J., Ravi B., Chandrasekaran K., McGoon M. Impact of pulmonary hypertension on the outcomes of noncardiac surgery. J Am Coll Cardiol. 2005 ; 45: 1691-1699.
4. Barst RJ, McGoon M., Torbicki A., et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2004 ; 43 (Suppl): 40-47.
5. Rubin L. Introduction: diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004 ; 126 (Suppl): 7-10.
6. Simonneau G., Galie N., Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004 ; 43 (suppl): 5-12.
7. McGoon M., Gutterman D., Steen V., et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension. Chest. 2004 ; 126 (Suppl): 14-34.
8. Chu J., Kao P., Faul J., Doyle R. High prevalence of autoimmune thyroid disease in pulmonary arterial hypertension. Chest. 2002 ; 122: 1668-1673.
9. Badesch D., Abman S., Ahearn G., et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004 ; 126 (Suppl): 35-62.
10. Rich S., Kaufmann E., Levy P. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension [abstract]. N Engl J Med. 1992 ; 327: 76-81.
11. Ogata M., Ohe M., Shirato K., et al. Effects of a combination therapy of anticoagulant and vasodilator on the long-term prognosis of primary pulmonary hypertension. Jpn Circ J. 1993 ; 57: 63-69.
12. Sitbon O., Humbert M., Ioos V., et al. Who benefits from long-term calcium-channel blocker therapy in primary pulmonary hypertension [abstract]. Am J Respir Crit Care Med. 1993 ; 167.
13. Sitbon O., Humbert M., Jais X., et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005 ; 111: 3105-3111.
14. Partanen J., Nieminen M., Luomanmaki K. Death in a patient with primary pulmonary hypertension after 20 mg of nifedipine [correspondence]. N Engl J Med. 1993 ; 329: 812-813.
15. Christman B., McPherson C., Newman J., et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992 ; 327: 70-75.
16. Tuder R., Cool C., Geraci M., et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med. 1999 ; 159: 1925-1932.
17. McLaughlin V., Shillington A., Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002 ; 106: 1477-1482.
18. Sitbon O., Humbert M., Nunes H., et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002 ; 40: 780-788.
19. Barst R., Rubin LJ, Long W., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996 ; 334: 296-302.
20. Badesch D., Tapson V., McGoon M., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med. 2000 ; 132: 425-434.
21. Barst R., Rubin L., McGoon M., et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med. 1994 ; 121: 409-415.
22. Shapiro S., Oudiz R., Cao T., et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol. 1997 ; 30: 343-349.
23. McLaughlin V., Genthner D., Panella M., et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med. 1998 ; 338: 273-277.
24. McLaughlin V., Gaine S., Barst R., et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol. 2003 ; 41: 293-299.
25. Simonneau G., Barst R., Galie N., et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002 ; 165: 800-804.
26. Oudiz R., Schilz R., Barst R., et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest. 2004 ; 126: 420-427.
27. Laliberte K., Arneson C., Jeffs R., Hunt T., Wade M. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol. 2004 ; 44: 209-214.
28. Olschewski H., Simonneau G., Galie N., et al. Aerosolized iloprost randomized study group: inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002 ; 347: 322-339.
29. Langer F., Wilhelm W., Tscholl D., et al. Intraoperative inhalation of the long-acting prostacyclin analog iloprost for pulmonary hypertension. J Thorac Cardiovasc Surg. 2003 ; 126: 874-875.
30. Rex S., Busch T., Vettelschoss M., de Rossi L., Rossaint R., Buhre W. Intraoperative management of severe pulmonary hypertension during cardiac surgery with inhaled iloprost. Anesthesiology. 2003 ; 99: 745-747.
31. Schroeder R., Wood G., Plotkin J., Kuo P. Intraoperative use of inhaled PGI2 for acute pulmonary hypertension and right ventricular failure. Anesth Analg. 2000 ; 91: 291-295.
32. Stewart D., Levy R., Cernacek P., Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med. 1991 ; 114: 464-469.
33. Pepke-Zaba J., Morrell N. The endothelin system and its role in pulmonary arterial hypertension (PAH). Thorax. 2005 ; 60: 443-444.
34. Channick R., Simonneau G., Sitbon O., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo controlled study [abstract]. Lancet. 2001 ; 358: 1119-1123.
35. Sitbon O., Badesch D., Channick R., et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest. 2003 ; 124: 247-254.
36. Rubin LJ, Badesch D., Barst R., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002 ; 346: 896-903.
37. McLaughlin V., Sitbon O., Badesch D., et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J. 2005 ; 25: 244-249.
38. Hoeper M., Halank M., Marx C., et al. Bosentan therapy for portopulmonary hypertension. Eur Respir J. 2005 ; 25: 502-508.
39. Hughes R., George P., Parameshwar J., et al. Bosentan in inoperable chronic thromboembolic pulmonary hypertension. Thorax. 2005 ; 60: 707.
40. Barst R., Langleben D., Frost A., et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004 ; 169: 441-447.
41. Langleben D., Hirsch A., Shalit E., Lesenko L., Barst R. Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest. 2004 ; 126: 1377-1381.
42. Barst R., Langleben D., Badesch D., et al. The STRIDE-2 Trial: does selectivity matter in endothelin antagonism for PAH? [abstract]. Proc Am Thorac Soc. 2005 ; 2: A300.
43. Galie N., Badesch D., Oudiz R., et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2005 ; 46: 529-535.
44. Hanson K., Burns F., Rybalkin S., et al. Developmental changes in lung cGMP phosphodiesterase-5 activity, protein, and message. Am J Respir Crit Care Med. 1998 ; 157: 279-288.
45. Hanson K., Ziegler J., Rybalkin S., et al. Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity. Am J Physiol. 1998 ; 275: L931 - L941.
46. Bharani A., Mathew V., Sahu A., et al. The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension. Indian Heart J. 2003 ; 55: 55-59.
47. Sastry B., Narasimhan C., Reddy N., et al. A study of clinical efficacy of sildenafil in patients with primary pulmonary hypertension. Indian Heart J. 2002 ; 54: 410-414.
48. Ghofrani H., Schermuly R., Rose F., et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med. 2003 ; 167: 1139-1141.
49. Michelakis E., Tymchak W., Lien D., et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation. 2002 ; 105: 2398-2403.
50. Doyle R. Early Diagnosis and Treatment of Pulmonary Arterial Hypertension. Medscape Pulmonary Medicine 2005. Available at: www.medscape.com/viewarticle/507344.
51. Hill N. Therapeutic Options for the Treatment of Pulmonary Hypertension. Medscape Pulmonary Medicine 2005. Available at: www.medscape.com/viewarticle/ 511756.
52. Wilkins M., Paul G., Strange J., et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med. 2005 ; 171: 1292-1297.
53. Preston I., Klinger J., Houtches J., Nelson D., Farber H., Hill N. Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension. Respir Med. 2005 ; 99: 1501-1510.
54. Ghofrani H., Voswinckel R., Reichenberger F., et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol. 2004 ; 44: 1488-1496.
55. Palmieri E., Affuso F., Fazio S., Lembo D. Tadalafil in primary pulmonary arterial hypertension. Ann Intern Med. 2004 ; 141: 743-744.
56. Hoeper M., Taha N., Bekjarova A., Gatzke R., Spiekerkoetter E. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids [abstract]. Eur Respir J. 2003 ; 22: 330-334.
57. Seyfarth H., Pankau H., Hammerschmidt S., Schauer J., Wirtz H., Winkler J. Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy [abstract]. Chest. 2005 ; 128: 709-713.
58. Humbert M., Barst R., Robbins I., et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004 ; 24: 353-359.
59. Ghofrani H., Rose F., Schermuly R., et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol. 2003 ; 42: 158-164.
60. Stiebellehner L., Petkov V., Vonbank K., et al. Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. Chest. 2003 ; 123: 1293-1295.
61. Wilkens H., Guth A., Konig J., et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation. 2001 ; 104: 1218-1222.
62. Hoeper M., Faulenbach C., Golpon H., Winkler J., Welte T., Niedermeyer J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J. 2004 ; 24: 1007-1010.
63. Fuster V., Steele P., Edwards W., Gersh B., McGoon M., Frye R. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation. 1984 ; 70: 580-587.
64. Rich S., Seidlitz M., Dodin E., et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest. 1998 ; 114: 787-792.
65. Reitz B., Wallwork J., Hunt S., et al. Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. N Engl J Med. 1982 ; 306: 557-564.
66. Doyle R., McCrory DC, Channick R., Simonneau G., Conte J. Surgical treatments/interventions for pulmonary arterial hypertension. Chest. 2004 ; 126 (Suppl): 63-71.
67. Glanville A., Burke C., Theodore J., et al. Primary pulmonary hypertension; length of survival in patients referred for heart-lung transplantation. Chest. 1987 ; 91: 675-681.
68. Kerstein D., Levy P., Hsu D., et al. Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension. Circulation. 1995 ; 91: 2028-2035.
69. Bergin C., Sirlin C., Hauschildt J., et al. Chronic thromboembolism: diagnosis with helical CT and MR imaging with angiographic and surgical correlation. Radiology. 1997 ; 204: 695-702.
70. Bergin C., Hauschildt J., Brown M., et al. Identifying the cause of unilateral hypoperfusion in patients suspected to have chronic pulmonary thromboembolism: diagnostic accuracy of helical CT and conventional angiography. Radiology. 1999 ; 213: 743-749.
71. Moser K., Daily P., Peterson K., et al. Thromboendarterectomy for chronic, major-vessel thromboembolic pulmonary hypertension: immediate and long-term results in 42 patients. Ann Intern Med. 1987 ; 107: 560-565.
72. Gilbert T., Gaine S., Rubin L., Sequireira A. Short outcome and predictors of adverse events following pulmonary thromboendarecterectomy. World J Surg. 1998 ; 22: 1029-1033.
73. International guidelines for the selection of lung transplant patients. The American Society for Transplant Physicians (ASTP)/American Thoracic Society(ATS)/European Respiratory Society(ERS)/International Society for Heart and Lung Transplantation(ISHLT). Am J Respir Crit Care Med. 1998 ; 158: 335-339.
74. Hertz M., Mohacsi P., Taylor D., et al. The registry of the International Society of Heart and Lung Transplantation: twentieth official report. J Heart Lung Transplant. 2003 ; 22: 610-615.
75. Boujoukos A., Martich G., Vega J., et al. Reperfusion injury in single lung transplant recipients with pulmonary hypertension and emphysema. J Heart Lung Transplant. 1997 ; 16: 440-448.
76. Cooper J., Patterson G., Trulock E. Results of single and bilateral lung transplantation in 131 consecutive recipients. Washington University Lung Transplant Group. J Thorac Cardiovasc Surg. 1994 ; 107: 460-470.
77. Guarracino F., Cariello C., Danella A., et al. Right ventricular failure: physiology and assessment. Minerva Anestesiol. 2005 ; 71: 307-312.
78. De Marco T, Chatterjee K. Refractory heart failure: a therapeutic approach. J Intensive Care Med. 1996 ; 11: 121-148.
79. Mebazaa A., Karpati P., Renaud E., Algotsson L. Acute right ventricular failure-from pathophysiology to new treatments. Intensive Care Med. 2004 ; 30: 185-196.
80. Packer M. Vasodilator therapy for primary pulmonary hypertension: limitations and hazards. Ann Intern Med. 1985 ; 103: 258-270.
81. McNeil K., Dunning J., Morrell N. The pulmonary physician in critical care: 13. The pulmonary circulation and right ventricular failure in the ITU. Thorax. 2003 ; 58: 157-162.
82. Borade S., Christenson J., O'Connor M., Lavoie A., Pohlman A., Hall J. Response to inhaled nitric oxide in patients with acute right heart syndrome. Am J Respir Crit Care Med. 1999 ; 159: 571-579,.
83. Ukkonen H., Saraste M., Akkila J., et al. Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther. 2000 ; 68: 522-531.
84. Slawsky M., Colucci W., Gottlieb S. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation. 2000 ; 102: 2222-2227.
85. Piazza G., Goldhaber S. The acutely decompensated right ventricle: pathways for diagnosis and management. Chest. 2005 ; 128: 1836-1852.
86. Hirsch L., Rooney M., Wat S., Kleinmann B., Mathru M. Norepinephrine and phenylephrine effects on right ventricular function in experimental canine pulmonary embolism. Chest. 1991 ; 100: 796-801.
87. Gold J., Cullilnane S., Chen J., et al. Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure [abstract]. Am J Cardiol. 2000 ; 85: 506-508.